NCT00608517 · REGISTRY CONDITION SEARCH

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: TERMINATED
Registry last update: 2014-05-20

RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: To look at the ability of umbilical cord blood cells from one or two unrelated donors to serve as a source of stem cells for people needing a bone marrow transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With 100-day Non-relapse Mortality

→

outcome · POSTED

Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells

→

outcome · POSTED

Number of Participants With Acute Graft-versus-host Disease (GVHD)

→

outcome · POSTED

Number of Participants Who Relapsed at 1 Year

→

outcome · POSTED

Number of Subjects With All-cause Mortality

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Participants With Chronic Graft Versus Host Disease (GVHD)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Patient and UCB Unit Selection: Inclusion Criteria: General (Adults and Pediatrics) Only one of the following should be present: * Acute leukemia (lymphocytic or myeloid or undifferentiated or biphenotypic) in complete remission 2 or beyond * Acute lymphocytic leukemia, Philadelphia chromosome positive in complete remission 1 or beyond * Acute myeloid leukemia in complete remission 1 if it has evolved from a myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS). * Acute leukemia in complete remission 1 if there is a failure to recover normal blood counts or the development of MDS following induction chemotherapy. * Therapy related acute leukemia in complete remission 1 or beyond * Chronic myeloid leukemia (CML) chronic phase-1 (imatinib failures, imatinib intolerance), or any CML beyond first chronic phase * Myelodysplastic syndromes (Intermediate -1 or higher risk by IPSS) * Therapy related MDS (irrespective of IPSS) * Multiple myeloma must have had prior chemotherapy or autologous transplant * Chronic lymphocytic leukemia must have failed two lines of conventional therapy but still chemosensitive to third line therapy. * Chemosensitive Non-Hodgkin's lymphoma or Hodgkin's lymphoma in CR or PR after failing induction therapy. * High risk acute leukemia/lymphoma eg Nk/T cell, HTLV associated leukemia/lymphoma, other T cell lymphoma/leukemia in first best response * For patients with acute leukemia-they must be in a remission (less than 5% leukemic marrow blasts) at time of study entry. Inclusion Criteria (Adults - 18 years or older) * Karnofsky score of \> 70% * Estimated creatinine clearance of \> 60 ml/min * Left ventricular ejection fraction of \>50% * Pulmonary function test with DLCO, FEV1 and FVC of \>60% * Total bilirubin and SGOT of \< 3.0 x upper limits of normal * Note: Age 18- 40 years for adult myeloablative conditioning Age \> 40 -50 years for adult reduced intensity conditioning Inclusion Criteria (Pediatrics - 18 years and younger) * Karnofsky or Lansky score of \> 70% * Estimated Creatinine clearance of \> 60 ml/min * Left ventricular ejection fraction of \>50% * Pulmonary function test with FEV1 and FVC of \>60% (for patients \>6 years of age) * Total bilirubin and SGOT of \< 3.0 x upper limits of normal * Note: All pediatric patients will receive myeloablative conditioning Inclusion Criteria - Donor Issues * No available HLA identical or 1 antigen/allele mismatched (Class I-A, B or Class II DR locus) related donor Inclusion Criteria: Umbilical Cord Blood Unit-HLA Typing * At least a HLA 4/6 match (Class I-A, B by low resolution, Class II-DR by high resolution) to recipient * For double UCB SCT each unit should be at least a 4/6 match (Class I-A,B by low resolution, Class II-DR by high resolution) to recipient, and should be at least a 4/6 match (Class I-A,B by low resolution, Class II-DR by high resolution) to each other Inclusion Criteria: Umbilical Cord Blood Unit-Cell dose * For Single UCB SCT: the unit will have ≥ 3.5 X 107 NC/kg of recipient body weight (For pediatric patients a cell dose ≥ 3.0 X 107 NC/kg of recipient body weight is acceptable). Recipient body weight will be determined as per standard guidelines. * For Double UCB SCT: (done only if no single UCB unit ≥ 3.5 X 107 NC/kg of recipient body weight is available for adults, and ≥ 3.0 X 107 NC/kg of recipient body weight is available for pediatric patients ) * The larger of the two units (UCB1) will have a minimum cell dose of 2.0 X 107 NC/kg of recipient body weight. The smaller of the two units (UCB2) will have a minimum of 0.5 X 107 NC/kg of recipient body weight. The total cell dose UCB1 + UCB2 will be ≥ 2.5 X 107 NC/kg of recipient body weight. -Adult patients eligible for a double UCB SCT but without an appropriate second UCB unit will be enrolled in the study if their single UCB unit contains ≥ 2.5 x 107 NC/kg recipient body weight. Exclusion Criteria * Organ dysfunction as per standard guidelines. Unable to give informed consent (for adults only) * Pregnant or lactating * Sexually active individuals capable of becoming pregnant or causing a pregnancy who are unable or unwilling to use appropriate contraceptives. * Active use of illicit drugs as evidenced by a positive toxicology screen for a substance not prescribed by a medical professional just prior to initiating the preparative regimen * Actively smoking as evidenced by a positive nicotine screen just prior to initiating the preparative regimen * HIV positive * Patients with other unrelated malignancies will be excluded except: * diagnosis of skin cancer (squamous cell or basal cell) * diagnosis of cervical dysplasia (CIN I-III) * any other malignancy which is currently in remission and was treated with curative intent more than 5 years preceding study entry * In patients with secondary MDS or secondary acute leukemias-the previous non-hematopoietic neoplasm should be in remission but can be within 5 years of study entry
healthy Volunteers: false
maximum Age: 50 Years
sex: ALL
std Ages: CHILD
ADULT

Treatment arms and interventions

arm Groups

description
Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
intervention Names
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: methylprednisolone
Radiation: total-body irradiation
label
Pediatric Myeloablative conditioning
type
EXPERIMENTAL
description
Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
intervention Names
Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: total-body irradiation
label
Adult Myeloablative conditioning
type
EXPERIMENTAL
description
Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
intervention Names
Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: total-body irradiation
label
Reduced-intensity conditioning
type
EXPERIMENTAL

interventions

arm Group Labels
Pediatric Myeloablative conditioning
description
Given IV
name
anti-thymocyte globulin
other Names
ATG
type
BIOLOGICAL
arm Group Labels
Adult Myeloablative conditioning
Pediatric Myeloablative conditioning
Reduced-intensity conditioning
description
Given IV
name
cyclophosphamide
other Names
Cytoxin
type
DRUG
arm Group Labels
Adult Myeloablative conditioning
Reduced-intensity conditioning
description
Given IV
name
fludarabine phosphate
other Names
Fludara
type
DRUG
arm Group Labels
Pediatric Myeloablative conditioning
description
Given IV
name
methylprednisolone
other Names
Medrol
type
DRUG
arm Group Labels
Adult Myeloablative conditioning
Pediatric Myeloablative conditioning
Reduced-intensity conditioning
description
Given daily for 1-4 days
name
total-body irradiation
type
RADIATION

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 6
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Evaluate the safety (as determined by the day 100 non-relapse mortality) and feasibility of single or double umbilical cord blood (UCB)stem cell transplant (SCT) in adult or pediatric patients with hematologic malignancies receiving graft-versus-host disease (GVHD) prophylaxis with tacrolimus and mycophenolate mofetil (MMF).
measure
Number of Participants With 100-day Non-relapse Mortality
time Frame
100 days

secondary Outcomes

description
Recovery of the neutrophil portion of white blood cells and showing complete donor cells.
measure
Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells
time Frame
42 days
description
Participants who exhibit acute GVHD.
measure
Number of Participants With Acute Graft-versus-host Disease (GVHD)
time Frame
100 days
measure
Number of Participants Who Relapsed at 1 Year
time Frame
1 year
description
Death from any cause at 100 days
measure
Number of Subjects With All-cause Mortality
time Frame
at 100 days
description
Overall survival at 1 year
measure
Overall Survival
time Frame
1 year
description
As opposed to acute GVHD, which is characterized by rash, cholestasis, and enteritis, chronic GVHD is characterized by nausea, anorexia, ocular and oral sicca, and other organ involvement
measure
Number of Participants With Chronic Graft Versus Host Disease (GVHD)
time Frame
100 days

Full study description

brief Summary: RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: To look at the ability of umbilical cord blood cells from one or two unrelated donors to serve as a source of stem cells for people needing a bone marrow transplant.
detailed Description: OBJECTIVES: Primary * To determine the safety (as assessed by the day 100 non-relapse mortality) and feasibility of single or double umbilical cord stem cell transplantation in patients with hematological malignancies receiving graft-versus-host disease (GVHD) prophylaxis comprising tacrolimus and mycophenolate mofetil (MMF). Secondary * To assess sustained donor engraftment, neutrophil recovery, platelet recovery, incidence and severity of acute graft-versus-host disease (GVHD) and chronic GVHD, relapse rate, 100-day all-cause mortality, overall survival, and immune reconstitution after single or double umbilical cord stem cell transplantation in patients with hematologic malignancies receiving graft-versus-host disease(GVHD) prophylaxis comprising tacrolimus and mycophenolate mofetil (MMF). OUTLINE: * Conditioning: Patients receive myeloablative or reduced-intensity conditioning regimen according to age and prior treatment. * Myeloablative conditioning (pediatric patients): Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1. * Myeloablative conditioning (adult patients 18-40 years old): Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1. * Reduced-intensity conditioning (patients over 40 and no more than 50 years old OR deemed ineligible for above myeloablative conditioning regimen due to previous treatment): Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1. * Umbilical cord blood transplantation (UCBT): All patients undergo single- or double-unit umbilical cord blood transplantation (UCBT)on day 0. * Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously or orally twice daily on days -2 to 180 followed by a tapering and mycophenolate mofetil IV or orally twice daily on days 0-100 followed by a tapering over the next 3 months. Patients also receive filgrastim (G-CSF) IV or subcutaneously beginning on day 0\* and continuing until blood counts recover. NOTE: \*In adult patients receiving a reduced intensity transplant, G-CSF will be started when the total white cell count falls below 2.5 x 109/L. After completion of study treatment, patients are followed monthly for 1 year and then every 2-4 months thereafter.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-cd9ae9fe526ff1d5ce21
requested nct id
NCT00608517
primary nct id
NCT00608517
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
2234ce85424b6a9cb974d9da843b123a47bf2b82a4f22a8a90f1870143afaf8a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-cd9ae9fe526ff1d5ce21
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00608517
occurrences
context exact
NCT00608517
end
11
exact text
NCT00608517
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/55/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d37b27648256c8ac93e862ef6c6dfe9177504a8b00f862af00998fe555e043bd
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f2900b156a1863d73e24
requested nct id
NCT00608517
primary nct id
NCT00608517
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Myelodysplastic+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
payload sha256
9c5f2d38315df529731543e0686c92fd4ce68ee206116305bb94bf479aff84a2
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f2900b156a1863d73e24
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00608517
occurrences
context exact
NCT00608517
end
11
exact text
NCT00608517
start
0
offset unit
unicode_code_points
query cond
Childhood Myelodysplastic Neoplasms
query disease state id
ds-myelodysplastic-neoplasms-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
source file sha256
a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
source json pointer
/studies/3/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d37b27648256c8ac93e862ef6c6dfe9177504a8b00f862af00998fe555e043bd
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Myelodysplastic+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-fd1682348584678b2f1a
requested nct id
NCT00608517
primary nct id
NCT00608517
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
payload sha256
ee36a71641ea6c175c8d5be08493acf19ca22f9e42c417975a27c6a36b134f2f
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-fd1682348584678b2f1a
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00608517
occurrences
context exact
NCT00608517
end
11
exact text
NCT00608517
start
0
offset unit
unicode_code_points
query cond
Childhood Chronic Myeloid Leukemia
query disease state id
ds-chronic-myeloid-leukemia-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
source json pointer
/studies/3/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d37b27648256c8ac93e862ef6c6dfe9177504a8b00f862af00998fe555e043bd
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice